Business
AVITA Medical Successfully Completes Australian Equity Raise
Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX)Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million), with participation from new and existing Australian shareholders VALENCIA, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the suc
About this update from Avita Medical, Inc.
[{"type":"image","alt":"AVITA Medical","displaySize":"","headline":null,"caption":"AVITA Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":96,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ejDr4RdwXqFCjMdbUOz.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dfd8c445a107185ef69e74538692859e","width":96,"height":115}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Private placement of approximately 17.2 million new CHESS Depositary Interests (“New CDIs”) quoted on the Australian Securities Exchange (ASX)","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"Issue price of A$1.32 per New CDI, raising approximately US$15 million (~A$23 million), with participation from new and existing Australian shareholders","length":152,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":294,"olType":false},{"type":"text","content":"VALENCIA, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced the successful completion of a private placement (the “Placement”) to institutional and professional investors in Australia to raise an approximate gross amount of US$15 million (approximately A$23 million) by way of the issue of approximately 17.2 million New CDIs at an offer price of A$1.32 per New CDI ("Offer Price").","length":530,"tagName":"p"},{"type":"text","content":"Proceeds from the Placement will be used for working capital requirements and will provide additional strategic flexibility to support continued growth of the Company’s therapeutic acute wound portfolio. This is expected to cover operations until free cash flow begins in 2026.","length":277,"tagName":"p"},{"type":"text","content":"“The strong support we received in this Placement reflects growing confidence in our strategy and the transformative potential of our therapeutic acute wound care portfolio,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “We welcome our new Australian shareholders and extend our sincere gratitude to our existing investors for their continued support.”","length":367,"tagName":"p"},{"type":"text","content...